Clinical Trial

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Study acronym: CAPCET-III
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided mCRC.
Trial Details
NCT Number NCT06616259
Lead Sponsor Meng Qiu
Conditions Colorectal Cancer (CRC), Capecitabine, Cetuximab
Enrollment 452 participants
Start Date 2024-09-26
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-27